KR20230024928A - 알카프타딘과 코르티코스테로이드의 병용 - Google Patents
알카프타딘과 코르티코스테로이드의 병용 Download PDFInfo
- Publication number
- KR20230024928A KR20230024928A KR1020227046470A KR20227046470A KR20230024928A KR 20230024928 A KR20230024928 A KR 20230024928A KR 1020227046470 A KR1020227046470 A KR 1020227046470A KR 20227046470 A KR20227046470 A KR 20227046470A KR 20230024928 A KR20230024928 A KR 20230024928A
- Authority
- KR
- South Korea
- Prior art keywords
- alcaftadine
- composition
- fluticasone
- corticosteroid
- topical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921053286 | 2020-06-15 | ||
| IN201921053286 | 2020-06-15 | ||
| PCT/IB2021/055222 WO2021255622A1 (en) | 2020-06-15 | 2021-06-14 | Combination of alcaftadine and a corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230024928A true KR20230024928A (ko) | 2023-02-21 |
Family
ID=76523259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227046470A Pending KR20230024928A (ko) | 2020-06-15 | 2021-06-14 | 알카프타딘과 코르티코스테로이드의 병용 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230218630A1 (https=) |
| EP (1) | EP4164614A1 (https=) |
| JP (1) | JP7791119B2 (https=) |
| KR (1) | KR20230024928A (https=) |
| CN (1) | CN115701988A (https=) |
| AU (1) | AU2021291684A1 (https=) |
| BR (1) | BR112022024840A2 (https=) |
| CA (1) | CA3181959A1 (https=) |
| CL (1) | CL2022003534A1 (https=) |
| MX (1) | MX2022015965A (https=) |
| WO (1) | WO2021255622A1 (https=) |
| ZA (1) | ZA202212128B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| JP7606530B2 (ja) | 2020-03-24 | 2024-12-25 | シラノ セラピューティクス， インコーポレイテッド | コロナウイルス感染症による化学感覚機能障害の治療 |
| US20240173331A1 (en) | 2021-04-01 | 2024-05-30 | Alkem Laboratories Limited | Nasal compositions comprising alcaftadine |
| CA3246013A1 (en) * | 2022-01-06 | 2023-07-13 | Cyrano Therapeutics, Inc. | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS |
| WO2024228988A2 (en) * | 2023-05-02 | 2024-11-07 | Cyrano Therapeutics, Inc. | Treatment for taste and smell loss |
| GR1010821B (el) * | 2023-11-09 | 2024-11-15 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3877904D1 (de) | 1987-11-13 | 1993-03-11 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| IL101850A (en) | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them |
| DE19947234A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und Antihistaminika |
| KR20050044550A (ko) * | 2001-12-05 | 2005-05-12 | 알콘, 인코퍼레이티드 | 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도 |
| PL1919450T3 (pl) | 2005-09-01 | 2014-11-28 | Meda Ab | Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych |
| BRPI0710085B8 (pt) * | 2006-03-31 | 2021-05-25 | Vistakon Pharmaceutical Llc | composições oftálmicas e seus kits |
| US8569273B2 (en) * | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| WO2011141929A2 (en) * | 2010-05-11 | 2011-11-17 | Cadila Healthcare Limited | Aqueous pharmaceutical compositions of fluticasone and olopatadine |
| CN102283849A (zh) * | 2011-06-29 | 2011-12-21 | 北京阜康仁生物制药科技有限公司 | 一种含有阿卡他定的药物组合物 |
| RU2652352C2 (ru) * | 2012-12-17 | 2018-04-25 | Глаксо Груп Лимитед | Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний |
| MX367674B (es) * | 2013-09-13 | 2019-08-30 | Glenmark Specialty Sa | Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina. |
| WO2019022225A1 (ja) | 2017-07-28 | 2019-01-31 | 参天製薬株式会社 | アルカフタジン又はその塩を含有する水性医薬組成物 |
-
2021
- 2021-06-14 WO PCT/IB2021/055222 patent/WO2021255622A1/en not_active Ceased
- 2021-06-14 KR KR1020227046470A patent/KR20230024928A/ko active Pending
- 2021-06-14 EP EP21733564.5A patent/EP4164614A1/en active Pending
- 2021-06-14 JP JP2022577618A patent/JP7791119B2/ja active Active
- 2021-06-14 CN CN202180040805.7A patent/CN115701988A/zh active Pending
- 2021-06-14 US US17/997,656 patent/US20230218630A1/en active Pending
- 2021-06-14 CA CA3181959A patent/CA3181959A1/en active Pending
- 2021-06-14 BR BR112022024840A patent/BR112022024840A2/pt unknown
- 2021-06-14 MX MX2022015965A patent/MX2022015965A/es unknown
- 2021-06-14 AU AU2021291684A patent/AU2021291684A1/en active Pending
-
2022
- 2022-11-07 ZA ZA2022/12128A patent/ZA202212128B/en unknown
- 2022-12-12 CL CL2022003534A patent/CL2022003534A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115701988A (zh) | 2023-02-14 |
| ZA202212128B (en) | 2024-04-24 |
| MX2022015965A (es) | 2023-03-14 |
| AU2021291684A1 (en) | 2022-12-08 |
| JP2023530166A (ja) | 2023-07-13 |
| CA3181959A1 (en) | 2021-12-23 |
| US20230218630A1 (en) | 2023-07-13 |
| EP4164614A1 (en) | 2023-04-19 |
| JP7791119B2 (ja) | 2025-12-23 |
| WO2021255622A1 (en) | 2021-12-23 |
| CL2022003534A1 (es) | 2023-06-23 |
| BR112022024840A2 (pt) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7791119B2 (ja) | アルカフタジンとコルチコステロイドの組み合わせ | |
| EP2522365B1 (en) | Compositions comprising azelastine and methods of use thereof | |
| JP5683719B2 (ja) | ベポタスチン組成物 | |
| US12274702B2 (en) | Nasal compositions comprising alcaftadine | |
| JP5785360B2 (ja) | 炎症病態またはアレルギー病態を治療するための、アゼラスチンとコルチコステロイドとを含む医薬製剤 | |
| US6780398B1 (en) | Aqueous nasal formulation | |
| TW201026339A (en) | Corticosteroid compositions and methods of treatments thereof | |
| US20150080355A1 (en) | Pharmaceutical Compositions Comprising Ebastine and Fluticasone | |
| US20140194400A1 (en) | Nasal Pharmaceutical Formulation | |
| RU2854644C1 (ru) | Композиции для интраназального применения, содержащие алкафтадин | |
| JP7391026B2 (ja) | モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療 | |
| WO2015009776A1 (en) | Low dose corticosteroid microemulsion compositions and methods of treatments thereof | |
| WO2006097458A1 (en) | Novel combination | |
| RU2798030C2 (ru) | Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина | |
| RU2687551C2 (ru) | Стабильная фармацевтическая композиция с фиксированной дозой, содержащая мометазон и олопатадин | |
| EA037259B1 (ru) | Применение фармацевтической композиции с фиксированной дозой, содержащей мометазон и азеластин, для лечения аллергического ринита и способ лечения аллергического ринита | |
| EA047266B1 (ru) | Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина | |
| NZ620005B2 (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
| CN101757635A (zh) | 采用环糊精包合醋丙甲泼尼龙的鼻用药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |